SELLAS Life Sciences Group, Inc. (SLS) |
|
3.25 -0.15 (-4.41%)
|
01-27 16:00 |
|
Open: |
3.43 |
Pre. Close: |
3.4 |
|
High:
|
3.43 |
Low:
|
3.17 |
|
Volume:
|
183,360 |
Market Cap:
|
67(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:48:00 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 4.18 One year: 4.88 |
| Support: |
Support1: 2.66  Support2: 2.09 |
| Resistance: |
Resistance1: 3.57 Resistance2: 4.18 |
| Pivot: |
3.07 |
| Moving Average: |
MA(5): 3.38 MA(20): 2.93
MA(100): 2.79 MA(250): 3.36 |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 78 %D(3): 83.3 |
| RSI: |
RSI(14): 59.3 |
| 52-week: |
High: 7.4 Low: 1.76 |
| Average Vol(K): |
3-Month: 285 (K) 10-Days: 203 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SLS ] has closed below upper band by 34.6%. Bollinger Bands are 27.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.43 - 3.46 |
3.46 - 3.47 |
|
Low:
|
3.12 - 3.15 |
3.15 - 3.17 |
|
Close:
|
3.22 - 3.25 |
3.25 - 3.28 |
|
Company Description |
|
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York. |
Headline News |
Sun, 29 Jan 2023
SLS Rocket Exceeds Expectations, Preparations Commence for ... - autoevolution
Sat, 28 Jan 2023
NASA's Artemis Aces Performance Tests, Preparing to Support Crewed Mission | Weather.com - The Weather Channel
Fri, 27 Jan 2023
NASA’s ‘Mega Moon Rocket’ aced first flight and is ready for crewed Artemis II launch - TechCrunch
Fri, 27 Jan 2023
Data from SLS Flight Prepares NASA for Future Artemis Missions – Artemis - NASA Blogs
Fri, 27 Jan 2023
Data from First SLS Flight to Prepare NASA for Future Artemis Missions - NASA
Fri, 27 Jan 2023
SLS announces revised 2nd Qtr. Honor Roll – WRBI Radio - Country 103.9 WRBI
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
21 (M) |
|
% Held by Insiders
|
2.034e+007 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
1,150 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
842.2 |
|
Return on Equity (ttm)
|
-55.6 |
|
Qtrly Rev. Growth
|
1e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-91.59 |
|
EBITDA (p.s.)
|
3.42593e+006 |
|
Qtrly Earnings Growth
|
-2.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-24 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.04 |
|
Price to Cash Flow
|
11.5 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.23e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-11-07 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
